Hims & Hers Health (HIMS) is down about 3.8% in today’s session, with the move largely tracking renewed skepticism around the company’s 2026 profit trajectory as it reshapes its U.S. weight-loss offering. Recent analyst commentary has emphasized that stepping back from aggressively marketing compounded GLP-1s and investing more heavily in labs/supply-chain capabilities can pressure near-term margins and earnings power, even if it supports a more durable long-term model.

Investors remain sensitive to headline risk tied to compounded semaglutide. Novo Nordisk filed a patent infringement lawsuit in February 2026 alleging Hims’ compounded semaglutide activity infringes a semaglutide-related patent, keeping uncertainty elevated around what Hims can offer, how it can market it, and what legal or settlement costs could look like. Even without a new court filing today, that backdrop can amplify routine down days, especially when the stock is already being valued on expectations for continued growth in weight-loss care.

Near-term, traders will look for (a) any incremental updates on GLP-1 product availability and pricing on the platform, (b) signals that customer growth can offset pressure from a more constrained compounded GLP-1 posture, and (c) any litigation developments that clarify downside risk. Investors are also likely to focus on the next earnings cycle for updated guidance on revenue growth versus profitability as the company reallocates spending toward infrastructure and compliance.